PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date

A Cherubini, E Casirati, M Tomasi… - Expert Opinion on …, 2021 - Taylor & Francis
Introduction An interaction between metabolic triggers and inherited predisposition
underpins the development and progression of non alcoholic fatty liver disease (NAFLD) …
被引用次数：37 相关文章

PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date

A Cherubini, E Casirati, M Tomasi, L Valenti - EXPERT OPINION ON …, 2021 - air.unimi.it
Introduction An interaction between metabolic triggers and inherited predisposition
underpins the development and progression of nonalcoholic Fatty Liver disease (NAFLD) …

PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date

A Cherubini, E Casirati, M Tomasi… - Expert opinion on …, 2021 - pubmed.ncbi.nlm.nih.gov
Introduction An interaction between metabolic triggers and inherited predisposition
underpins the development and progression of non alcoholic fatty liver disease (NAFLD) …

PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date.

A Cherubini, E Casirati, M Tomasi… - Expert Opinion on …, 2021 - europepmc.org
An interaction between metabolic triggers and inherited predisposition underpins the
development and progression of non alcoholic fatty liver disease (NAFLD) and fatty liver …
[PDF] unimi.it

[PDF][PDF] PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date

A Cherubini, E Casirati, M Tomasi, L Valenti - 2021 - air.unimi.it
Introduction: An interaction between metabolic triggers and inherited predisposition
underpins the development and progression of nonalcoholic Fatty Liver disease (NAFLD) …